BACKGROUND: Heme oxygenase 1 (HO-1) degrades heme and protects against oxidative stress. In vitro and animal models suggest that HO-1 is beneficial in several diseases (e.g., postoperative ileus, gastroparesis, acute pancreatitis, and colitis). However, the only drugs (i.e., hemin and heme arginate) which pharmacologically upregulate HO-1 in humans are expensive and can only be administered intravenously. Our aims were to compare the effects of placebo, aspirin, and simvastatin alone, and with α-lipoic acid, on HO-1 protein concentration and activity in humans. METHODS: This randomized, double-blind, placebo-controlled study compared the effects of three oral regimens administered for 7 days, i.e., placebo; aspirin (325 mg twice daily) and simvastatin (40 mg twice daily); aspirin, simvastatin, and the sodium salt of R- α-lipoic acid (NaRLA, 600 mg three times daily) on markers of HO-1 activation (i.e., plasma HO-1 protein concentration and venous monocyte HO-1 protein activity) in 18 healthy subjects (14 females). Markers of HO-1 activation were evaluated at baseline, days 2, and 7. KEY RESULTS:Baseline HO-1 protein concentrations and activity were similar among the three groups. Compared to placebo, aspirin and simvastatin combined, or together with NaRLA did not affect HO-1 protein concentration or activity at 2 or 7 days. HO-1protein concentrations and activity were correlated on day 7 (r = 0.75, p = 0.0004) but not at baseline and on day 2. CONCLUSIONS & INFERENCES: At therapeutic doses, aspirin, simvastatin, and α-lipoic acid do not increase plasma HO-1 protein concentration or venous monocyte HO-1 activity in healthy humans.
RCT Entities:
BACKGROUND:Heme oxygenase 1 (HO-1) degrades heme and protects against oxidative stress. In vitro and animal models suggest that HO-1 is beneficial in several diseases (e.g., postoperative ileus, gastroparesis, acute pancreatitis, and colitis). However, the only drugs (i.e., hemin and heme arginate) which pharmacologically upregulate HO-1 in humans are expensive and can only be administered intravenously. Our aims were to compare the effects of placebo, aspirin, and simvastatin alone, and with α-lipoic acid, on HO-1 protein concentration and activity in humans. METHODS: This randomized, double-blind, placebo-controlled study compared the effects of three oral regimens administered for 7 days, i.e., placebo; aspirin (325 mg twice daily) and simvastatin (40 mg twice daily); aspirin, simvastatin, and the sodium salt of R- α-lipoic acid (NaRLA, 600 mg three times daily) on markers of HO-1 activation (i.e., plasma HO-1 protein concentration and venous monocyte HO-1 protein activity) in 18 healthy subjects (14 females). Markers of HO-1 activation were evaluated at baseline, days 2, and 7. KEY RESULTS: Baseline HO-1 protein concentrations and activity were similar among the three groups. Compared to placebo, aspirin and simvastatin combined, or together with NaRLA did not affect HO-1 protein concentration or activity at 2 or 7 days. HO-1 protein concentrations and activity were correlated on day 7 (r = 0.75, p = 0.0004) but not at baseline and on day 2. CONCLUSIONS & INFERENCES: At therapeutic doses, aspirin, simvastatin, and α-lipoic acid do not increase plasma HO-1 protein concentration or venous monocyte HO-1 activity in healthy humans.
Authors: Angelo A Chora; Paulo Fontoura; Andreia Cunha; Teresa F Pais; Sílvia Cardoso; Peggy P Ho; Lowen Y Lee; Raymond A Sobel; Lawrence Steinman; Miguel P Soares Journal: J Clin Invest Date: 2007-01-25 Impact factor: 14.808
Authors: Sophie Brouard; Pascal O Berberat; Edda Tobiasch; Mark P Seldon; Fritz H Bach; Miguel P Soares Journal: J Biol Chem Date: 2002-03-05 Impact factor: 5.157
Authors: Kyoung Moo Choi; Simon J Gibbons; Tien V Nguyen; Gary J Stoltz; Matthew S Lurken; Tamas Ordog; Joseph H Szurszewski; Gianrico Farrugia Journal: Gastroenterology Date: 2008-09-11 Impact factor: 22.682
Authors: Nina Grosser; Aida Abate; Stefanie Oberle; Hendrik J Vreman; Phyllis A Dennery; Jan C Becker; Thorsten Pohle; Daniel S Seidman; Henning Schröder Journal: Biochem Biophys Res Commun Date: 2003-09-05 Impact factor: 3.575
Authors: A E Bharucha; S L Daley; P A Low; S J Gibbons; K M Choi; M Camilleri; J J Saw; G Farrugia; A R Zinsmeister Journal: Neurogastroenterol Motil Date: 2016-06-09 Impact factor: 3.598